The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index; 114 of the 199 sources its claims cite were checked for support.
Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook
Open accessAbstract
Major depressive disorder (MDD) is a highly prevalent and heterogeneous psychiatric disorder shaped by the interplay of genetic, environmental, and epigenetic factors. Histone modifications, particularly acetylation and methylation, have emerged as critical regulators of chromatin dynamics and gene expression in stress adaptation, neuroplasticity, and emotional regulation. This review synthesizes current evidence linking dysregulated histone deacetylases (HDACs) and histone methyltransferases (HMTs) to impaired neuroplasticity, neuroinflammation, mitochondrial dysfunction, and hypothalamic–pituitary–adrenal (HPA) axis hyperactivity in depression. We further evaluate the therapeutic potential of HDAC and HMT inhibitors, highlight their effects beyond transcriptional control, and discuss peripheral epigenetic biomarkers as candidate tools for patient stratification and treatment prediction. Emerging technologies, including single-cell and spatial epigenomics as well as CRISPR-based epigenetic editing, are outlined as future avenues toward precision medicine. While isoform specificity, off-target effects, and translational heterogeneity remain major challenges, targeting histone modifications represents a promising strategy for next-generation antidepressant development.
Overview
CoChat Summary
TL;DR
This narrative review synthesizes evidence that dysregulated histone acetylation and methylation—chiefly via HDACs and HMTs—contribute to depression pathophysiology through impaired neuroplasticity, neuroinflammation, mitochondrial dysfunction, and HPA-axis hyperactivity, and evaluates HDAC/HMT inhibitors as candidate antidepressants. It concludes that clinical translation remains early-stage, constrained by isoform specificity, off-target effects, and translational heterogeneity.
Key findings
- MDD affects over 280 million individuals globally, with global prevalence rising nearly 50% over the past three decades; histone hypoacetylation at H3K9ac and H4K12ac in hippocampus and prefrontal cortex is associated with reduced BDNF, SLC6A4, CREB, and monoamine-synthesis enzymes (TH, TPH) in chronic stress models.
- The mammalian HDAC family comprises 18 isoforms in four classes (I–IV); Class I and II isoforms appear most relevant to depression, with HDAC2/5 activity increased by chronic stress and HDAC5-mediated H4K12 deacetylation linked to stress vulnerability.
- Repressive methylation marks H3K9me3 (SETDB1) and H3K27me3 (EZH2) silence mood-relevant genes: SETDB1 loss derepresses Htr3a in cortical GABAergic interneurons producing anxiety/depression-like behavior in mice (partially reversed by 5-HT3 antagonists), while EZH2 inhibitors GSK126 and EPZ-6438 (tazemetostat) alleviate depressive-like behavior in preclinical models.
- HDAC inhibitors (SAHA, entinostat) show antidepressant, anti-inflammatory, and metabolic effects in animal models, but direct human evidence in depression is limited and large-scale randomized controlled trials are lacking; SAHA and entinostat have reached phase I/II oncology trials only.
Methods
- Narrative review integrating preclinical (rodent chronic unpredictable stress, chronic social defeat stress, prenatal stress), cellular, and clinical literature on histone modifications in MDD.
- Covers nucleosome biology, writer/eraser/reader enzymology, region- and sex-specific chromatin alterations (PFC, NAc, hippocampus/DG), HDAC/HMT pharmacology, peripheral biomarkers, and emerging technologies (single-cell/spatial epigenomics, CRISPR-dCas9 editing).
- No primary data, systematic search protocol, or meta-analysis is reported.
Limitations
- Stated: HDAC inhibitors display limited isoform selectivity and off-target activity; broad-spectrum inhibition raises systemic and neurocognitive safety concerns; epigenetic drugs act on interconnected networks with compensatory responses; temporal, regional, and cellular heterogeneity complicate prediction; animal models incompletely capture clinical heterogeneity, chronicity, and symptom profiles, with species-specific epigenetic differences; peripheral biomarkers lack multicenter longitudinal validation and their reflection of central pathology is uncertain; clinical evidence in depression remains early-phase.
- Evident from the text: as a narrative review without a stated search strategy or quality appraisal, the synthesis is selective and does not quantify effect sizes or assess risk of bias across cited studies; several mechanistic claims rest on non-depression models (spinal cord injury, UVB photoaging, cellular senescence, Alzheimer's disease).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
80 Valid · 10 Not valid · 42 Not checked · 69 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“HDAC5-mediated H4K12 deacetylation in the hippocampus contributes to stress vulnerability, indicating its value as a potential therapeutic target in susceptible populations (Dai et al., 2023; Li et al., 2024; Ershadi et al., 2021).”
§ Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook > Clinical and translational evidence > Current status of clinical research
What the sources say
- Disputedcites Dai et al., 2023 sourceExperimental — accuracy not yet measured
The Discussion reports that after chronic restraint stress, hippocampal HDAC9 increased while other HDACs did not show significant changes. The paper identifies HDAC9-mediated deacetylation of ANXA2—not HDAC5-mediated H4K12 deacetylation—as its mechanism for depression-like behavior in mice. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Not matchedcites Li et al., 2024
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites Ershadi et al., 2021 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In depression, altered epigenetic patterns have been observed in key genes related to neurodevelopment and neurotransmission, including the serotonin transporter gene (SLC6A4) and brain-derived neurotrophic factor (BDNF) (Jiang et al., 2019; Levy et al., 2018).”
§ Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook > Introduction
What the sources say
- Partly supportedcites Jiang et al., 2019 sourceExperimental — accuracy not yet measured
In “The Associations Between Methylation and Childhood Trauma” (page unavailable), the paper links higher SLC6A4 methylation with worse clinical presentation in major depressive disorder. It also reports altered BDNF methylation after childhood maltreatment and an association between BDNF and depressive symptoms, but does not establish that the BDNF methylation changes were observed in depression. (LLM, conf=0.85)
- Could not verifycites Levy et al., 2018 sourceExperimental — accuracy not yet measured
The Neuroplasticity: definition section mentions epigenetic regulation of genes involved in plasticity, but does not report altered epigenetic patterns in depression. The BDNF section discusses expression levels and a genetic variant, while the Amygdala section discusses a serotonin-transporter promoter variant; neither identifies an epigenetic alteration in BDNF or SLC6A4. Searches for epigenetic, DNA methylation, SLC6A4, and BDNF promoter methylation found no passage establishing the claim. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Histone modifications play a central role in the epigenetic regulation of depression by influencing chromatin structure and transcriptional control (Czarny et al., 2021; Nestler et al., 2016).”
§ Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook > Introduction
What the sources say
- Supportedcites Czarny et al., 2021 source
Section 3, “Histone Modifications,” links histone modifications to gene-expression control and identifies acetylation and methylation as major subjects of depression research. It explains that acetylation and deacetylation alter chromatin condensation and thereby regulate gene expression, while methylation can activate or repress transcription. (LLM, conf=0.93)
- Supportedcites Nestler et al., 2016 source
The Overview of Epigenetic Mechanisms (“Histones”) explains that histone modifications alter chromatin condensation and gene activity. “Histone Modifications in Adult Depression Models” links those modifications to depression-like behavior and changes in gene expression, supporting the paraphrase. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HDAC inhibitors directly modulate mitochondrial homeostasis.”
§ Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook > Epigenetic therapeutic targets: focus on HDACs and HMTs > HDAC and HMT modulators beyond gene expression
What the sources say
- Partly supportedcites Vizioli et al., 2020 sourceExperimental — accuracy not yet measured
The Results section reports that HDAC inhibitors improve mitochondrial function in senescent cells. The Discussion says the mechanism is unresolved and that indirect mechanisms are possible, so the paper does not establish that the modulation is direct. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HDAC inhibitors modulate inflammatory pathways beyond transcriptional control (Dai et al., 2025).”
§ Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook > Epigenetic therapeutic targets: focus on HDACs and HMTs > HDAC and HMT modulators beyond gene expression
What the sources say
- Partly supportedcites Dai et al., 2025 sourceExperimental — accuracy not yet measured
The Results section (‘SAHA inhibit UVB-induced inflammatory responses in HaCaT cells’) reports reduced phosphorylated NF-κB protein after treatment with SAHA, an HDAC inhibitor. This supports modulation of inflammatory signaling beyond changes in gene expression, but the study examines one inhibitor in UVB-exposed skin cells; it does not establish the claim for HDAC inhibitors generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
96 more claims · 36 with their cited sources checked
Create a free account to see all 201 claims and to verify the 2 references still open.
- It may state two separate claims as one. 90
- Probably not a substantial claim. 17
Citations
Cites
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Neocortical excitation/inhibition balance in information processing and social dysfunction
Yizhar, O., Fenno, L. E., Prigge, M., Schneider, F., Davidson, T. J., O’Shea, D. J., Sohal, V. S., Goshen, I., Finkelstein, J., Paz, J. T., et al. (2011) · Nature · doi:10.1038/nature10360 · Cited by 2,454
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
The Bidirectional Relationship of Depression and Inflammation: Double Trouble
Beurel, E., Toups, M., & Nemeroff, C. B. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.002 · Cited by 2,136 · cited 1×
“Clinically, MDD is marked by persistent low mood, anhedonia, cognitive impairment, and physical symptoms such as sleep and appetite disturbances (Beurel et al., 2020).”
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“SAHA exemplifies broad-spectrum inhibition (Marks et al., 2001; Duvic et al., 2007), whereas entinostat shows greater class I selectivity (Kiany et al., 2020).”
Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics
Jiang, S., Li, H., Zhang, L., Mu, W., Zhang, Y., Chen, T., Wu, J., Tang, H., Zheng, S., Liu, Y., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae973 · Cited by 1,804
Self-citationStructures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714 · cited 1×
“HDAC6 also contributes to mitochondrial trafficking and misfolded protein clearance (Perry et al., 2017; Finnin et al., 1999), highlighting the HDAC6–microtubule–mitochondria axis as an important regulatory node beyond chromatin-dependent mechanisms.”
Functions of Site-Specific Histone Acetylation and Deacetylation
Shahbazian, M. D., & Grunstein, M. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.052705.162114 · Cited by 1,635
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 2×
“The mammalian HDAC family consists of 18 isoforms categorized into four major classes (Classes I–IV) (Zhang et al., 2024; Glozak et al., 2005; Gallinari et al., 2007; Yang and Grégoire, 2005), as summarized in Table 1 (Vanaja et al., 2018; Johnstone, 2002; Gao et al., 2002; Tong et al., 2002;…”
Research works printed but not linked: 1
- 2025, Depressive disorder (depression)
Cited by
Epigenetic regulation in hypertension: mechanistic insights and environmental influences
Perla, S., Goud, A. C., Liu, M., Misra, S., Kumar, A., Srinivasamurthy, S. K., Samara, V. A., Nair, S., & Jain, S. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpag037
Chakraborty, W., Anand, A., & Roy, K. K. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111846
Epigenetic Control of Stress-Induced Depression: Emerging Roles of HDAC3 and HDAC6
Mohan, A. S., Narayanan, J., Kashid, V. A., Patel, R. J., & Prajapati, B. G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167313
“Changes in histone modifications have also been linked to neuroinflammation and neuronal injury in depression [7].”
Genetic, Epigenetic, and Environmental Contributions to Major Depressive Disorder Etiology
Kardan, R., Momeni, A., Shahreza, P. B., & Bayat, H. (2026) · IGI Global eBooks · doi:10.4018/979-8-2600-4270-0.ch001
Recent Advances in Autism Spectrum Disorder Research on Epigenetics and Personalised Medicine
Khosrofar, R., Morshedi, I., Behzadpour, M., Afzali, N., Hosseini, R. S., & Aghili, A. (2026) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.70184
Metadata
- Authors
- Lv, L.-Z., Wang, Z.-D., Ren, J.-J., Li, L.-H., Liu, X.-B., Li, J.-L., Zhu, H., Jiang, B., Han, Y.-P., Zhou, X.-M., Ren, L., & Chang, Z.
- Affiliations
- Heilongjiang University of Chinese Medicine (CN)
- Zhejiang Chinese Medical University (CN)
- Guangdong Medical College (CN)
- Corresponding author
- Chang, Zhuo
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2026-01-12
- Volume
- 16
- Pages
- 1722453-1722453
- ISSN
- 1664-8021 (ISSN-L)
- PMC
- PMC12832117
- OpenAlex
- W7122721022
- Cited by
- 7
- References
- 147
- Citations by year
- 2026: 7
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Genetics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82205163, 82174421)
- Natural Science Foundation of Heilongjiang Province (PL2024H220)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- histone modifications, major depressive disorder, histone deacetylase, histone methyltransferase, histone deacetylase inhibitors, epigenetic biomarkers, neuroplasticity, neuroinflammation, mitochondrial dysfunction, HPA axis hyperactivity, stress adaptation, emotion regulation, antidepressant drug development, precision medicine, spatial epigenomics, chromatin dynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook. https://app.cochat.ai/papers/10.3389/fgene.2025.1722453
- The paper
- Lv, L.-Z., Wang, Z.-D., Ren, J.-J., Li, L.-H., Liu, X.-B., Li, J.-L., Zhu, H., Jiang, B., Han, Y.-P., Zhou, X.-M., Ren, L., & Chang, Z. (2026). Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook. Frontiers in Genetics. https://doi.org/10.3389/fgene.2025.1722453
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.